AbbVie Stock Falls 4% -- What Investors Need to Know

Earnings season creates short-term winners and losers, companies whose shares rise or fall after they announce their quarterly updates. The good news is that among these short-term losers, there are plenty of long-term winners -- or companies that look attractive for investors focused on the long game even after a post-earnings dip.That seems to be the case with AbbVie (NYSE: ABBV). The pharmaceutical giant failed to impress Wall Street with its third-quarter results, leading to a dip on the heels of its earnings release. However, the drugmaker is still a buy. Here is more on AbbVie's recent results and prospects.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool